Ipsen expands early development pipeline with Simcere Zaiming's innovative antibody drug conjugate
Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugate SIM0613 is optimally designed for superior tumor penetration with robust preclinical eff
(Financial Post, 2025-12-22T06:00:39Z)